Testing how dapagliflozin affects anemia in heart failure
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This trial studies whether dapagliflozin (a heart-failure medicine) can improve anemia in people with heart failure. It may help explain why some patients feel better and how anemia changes when this medicine is used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 100 years old
- Your blood test (BNP or NT-proBNP) was high when you were admitted
- Your heart pumping strength (ejection fraction) is 50% or lower, with heart failure symptoms that are NYHA class II, III, or IV
- You have NOT taken an SGLT2 inhibitor like dapagliflozin in the last 3 months, and you’ve never had a bad reaction to this medicine group
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
This trial tests whether adding dapagliflozin (a medication that helps protect the heart and kidneys) helps people with heart failure who are also on peritoneal dialysis. It may offer extra support for your heart and kidney health.
This trial tests whether dapagliflozin, a diabetes medication, can safely increase red blood cell counts and reduce the need for transfusions in patients with lower-risk myelodysplastic syndromes (a blood disorder where the bone marrow doesn't make enough healthy blood cells). The goal is to help patients with anemia feel less tired and avoid frequent blood transfusions.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.